Features
Case Notes
Recent rulings of interest to you and your practice.
Features
The Golden Rule of Biological Inventions And the Written Description Requirement
In an ideal world, a business would have a patent practitioner everywhere at once: in the lab, in the office, and in the boardroom. The purpose of this article is to interpret a sphere of patent law related to the description of biological inventions in terms that are practical for researchers and business managers in the biotech industry who live in a non-ideal world.
Features
RIAA Tempers Tactics
In December, the RIAA announced that it would no longer look to file suit against individual file sharers and instead form relationships with ISPs that maintain the online accounts of the consumers.
Features
Case Notes
Recent litigation of interest to you and your practice.
Features
Product Liability Litigation
The different ' sometimes even higher ' product standards required by non-American countries can adversely affect product protection here in the United States, as plaintiff's attorneys can use these discrepancies to their advantage in litigation against product manufacturers.
Features
Preemption Beyond Drugs and Medical Devices
Although the issue of Federal Preemption has grabbed the headlines in medical device and pharmaceutical cases, those analyzing preemption's impact on plaintiff's failure-to-warn claims on other types of products that are subject to federal regulation are significant for their varied results.
Features
Trial Tactics in Psychiatrist Liability Cases
The average juror may not be aware of the extent of mental-health professionals' duty to protect innocent third parties from their dangerous patients, and they may be reluctant to hold these professionals responsible. Following are some strategies that will help to get the plaintiff's point of view across to the fact finder.
Features
Spoliation in a Medical Malpractice Case
Spoliation in the context of a medical malpractice case can raise many issues for lawyers representing doctors and hospitals. These issues can often be overlooked until it is too late to repair the damage done.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
- The Roadmap of Litigation AnalyticsLitigation analytics can be considered a roadmap of sorts — an important guide to ensure the legal professional arrives at the correct litigation strategy or business plan. However, like roadmaps, litigation analytics will only be useful if it's based on data that is complete and accurate.Read More ›
- Bankruptcy Sales: Finding a Diamond In the RoughThere is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.Read More ›
